Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Tapinarof, in embodiments crystalline polymorphs or co-crystals of Tapinarof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: Solid state forms of SEP-363856 HBr, SEP-363856 Fumarate, SEP-363856 R-camsylate and SEP-363856 S-camsylate and processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: Solid state forms of Mitapivat, Mitapivat hemisulfate, Mitapivat HCl, Mitapivat phosphate, Mitapivat hemisulfate:ascorbic acid and Mitapivat hemisulfate:adipic acid, processes for preparation thereof, pharmaceutical compositions there-of, and uses thereof are disclosed.

Abstract: The present disclosure encompasses a novel solid state form of Blarcamesine and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure encompasses solid state forms of SAGE-217, in embodiments SAGE-217:Oxalic acid Co-crystal, processes for preparation thereof, and pharmaceutical compositions thereof.

Abstract: The present disclosure relates to Branaplam solid state forms, Branaplam salts and solid states thereof, processes for preparation thereof, pharmaceutical compositions and methods of use thereof.

Abstract: The present invention provides a semipermeable membrane having enhanced alkaline stability and a method of forming a semipermeable membrane having enhanced alkaline stability, comprising steps of: providing an ultrafiltration (UF) base membrane, immersing said UF membrane in a solution comprising at least one substance selected from the group consisting of a polymer preferably polyethylenimine (PEI), a condensate solution and a mixture thereof, thereby forming reactive moieties upon said UF membrane, and forming at least one first layer upon at least portion of said UF base support membrane by immersing said UF base support membrane of step (b) in a solution comprising at least one ingredient selected from the group consisting of polymer preferably polyethylenimine (PEI), condensate solution and a mixture thereof thereby forming a cross-linked skin on the surface of said base membrane.

Abstract: The present disclosure relates to new salts of Vortioxetine, including butyrate, iso-butyrate, benzoate and propionate, solid state forms of the Vortioxetine salts, processes for the preparation thereof, pharmaceutical formulations/compositions thereof, and methods of use thereof.

Abstract: Solvent and acid stable ultrafiltration and nanofiltration membranes including a non-cross-linked base polymer having reactive pendant moieties, the base polymer being modified by forming a cross-linked skin onto a surface thereof, the skin being formed by a cross-linking reaction of reactive pendant moieties on the surface with an oligomer or another polymer as well as methods of manufacture and use thereof, including, inter alia separating metal ions from liquid process streams.

Abstract: The present invention provides a semipermeable membrane having enhanced alkaline stability and a method of forming a semipermeable membrane having enhanced alkaline stability, comprising steps of: providing an ultrafiltration (UF) base membrane, immersing said UF membrane in a solution comprising at least one substance selected from the group consisting of a polymer preferably polyethylenimine (PEI), a condensate solution and a mixture thereof, thereby forming reactive moieties upon said UF membrane, and forming at least one first layer upon at least portion of said UF base support membrane by immersing said UF base support membrane of step (b) in a solution comprising at least one ingredient selected from the group consisting of polymer preferably polyethylenimine (PEI), condensate solution and a mixture thereof thereby forming a cross-linked skin on the surface of said base membrane.

Abstract: Solvent and acid stable ultrafiltration and nanofiltration membranes including a non-cross-linked base polymer having reactive pendant moieties, the base polymer being modified by forming a cross-linked skin onto a surface thereof, the skin being formed by a cross-linking reaction of reactive pendant moieties on the surface with an oligomer or another polymer as well as methods of manufacture and use thereof, including, inter alia separating metal ions from liquid process streams.

Abstract: Solvent and acid stable ultrafiltration and nanofiltration membranes including a non-cross-linked base polymer having reactive pendant moieties, the base polymer being modified by forming a cross-linked skin onto a surface thereof, the skin being formed by a cross-linking reaction of reactive pendant moieties on the surface with an oligomer or another polymer as well as methods of manufacture and use thereof, including, inter alia separating metal ions from liquid process streams.